Business Context and Reporting Period
Company: Coherus BioSciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 28, 2016
Event: Entry into a Material Definitive Agreement (Sales Agreement).
Key Financial Metrics
This filing does not report operational financial metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data point disclosed is the potential capital raise:
- Maximum Gross Proceeds: Up to $100,000,000.
- Transaction Type: "At the market" equity offering program.
- Agent Compensation: 3.0% of gross proceeds of shares sold.
Material Changes
On October 28, 2016, the Company entered into a Sales Agreement with Cowen and Company, LLC. This agreement authorizes the Company to sell shares of its common stock from time to time through an "at the market" offering. The filing does not provide comparative financial data against prior periods as it is a transactional report rather than a periodic financial statement.
Guidance, Outlook, and Risks
- Management Discretion: The Company retains the right to set parameters for sales, including share count, timing, daily limits, and minimum price thresholds.
- Termination Rights: Both the Company and Cowen may terminate the agreement at any time in their sole discretion upon written notice.
- Obligation: The Company has no obligation to sell any shares and may suspend the program at any time.
- Legal Framework: Shares will be issued pursuant to a shelf registration statement on Form S-3 (File No. 333-208625).
Investor Verification Checklist
- Verify the current share price and market conditions to assess the potential dilution impact of a $100 million offering.
- Review the full Sales Agreement (Exhibit 1.1) for specific minimum price floors or daily volume caps set by management.
- Confirm the status of the Company's Form S-3 shelf registration (File No. 333-208625) to ensure eligibility for future sales.
- Monitor subsequent filings to determine if and when the Company elects to execute sales under this agreement.